Ticagrelor

Active ingredient: Ticagrelor

In short: Ticagrelor is indicated to reduce the risk of a first MI or stroke in patients with coronary artery disease (CAD) at high risk for such events . While use is not limited to this setting, the efficacy of Ticagrelor was established in a population with type 2 diabetes mellitus (T2DM).

Forms & strengthsTicagrelor tablets 90 mg are supplied as a round, biconvex, yellow, film-coated tablet debossed with a “HU” on one side and “90” on the other side.
LabelHisun Pharmaceuticals USA, Inc.
Label updatedNov 04, 2026

What is Ticagrelor used for?

Ticagrelor is indicated to reduce the risk of a first MI or stroke in patients with coronary artery disease (CAD) at high risk for such events

. While use is not limited to this setting, the efficacy of Ticagrelor was established in a population with type 2 diabetes mellitus (T2DM).

Ticagrelor is indicated to reduce the risk of stroke in patients with acute ischemic stroke (NIH Stroke Scale score ≤5) or high-risk transient ischemic attack (TIA)

.

⚠ Boxed warning (FDA's strongest warning)

Ticagrelor, like other antiplatelet agents, can cause significant, sometimes fatal bleeding (

5.1,

6.1).

Do not use ticagrelor in patients with active pathological bleeding or a history of intracranial hemorrhage (

4.1,

4.2).

Do not start ticagrelor in patients undergoing urgent coronary artery bypass graft surgery (CABG) (

5.1,

6.1).

If possible, manage bleeding without discontinuing ticagrelor. Stopping ticagrelor increases the risk of subsequent cardiovascular events (

5.2).

Ticagrelor dosage

Advise patients who miss a dose of ticagrelor tablets to take their next dose at its scheduled time.

For patients who are unable to swallow tablets whole, ticagrelor tablets can be crushed, mixed with water, and drunk. The mixture can also be administered via a nasogastric tube (CH8 or greater) .

Do not administer ticagrelor tablets with another oral P2Y

12platelet inhibitor.

Avoid aspirin at doses higher than recommended .

Administer 60 mg of ticagrelor tablets twice daily.

Generally, use ticagrelor tablets with a daily maintenance dose of aspirin of 75 mg to 100 mg

.

Initiate treatment with a 180 mg loading dose of ticagrelor tablets and then continue with 90 mg twice daily for up to 30 days.

Administer the first maintenance dose 6 to 12 hours after the loading dose.

Use ticagrelor tablets with a loading dose of aspirin (300 mg to 325 mg) and a daily maintenance dose of aspirin of 75 mg to 100 mg

.

A patient who misses a dose of ticagrelor tablets should take one tablet (their next dose) at its scheduled time.

For patients who are unable to swallow tablets whole, ticagrelor tablets can be crushed, mixed with water and drunk. The mixture can also be administered via a nasogastric tube (CH8 or greater)

.

Do not administer ticagrelor tablets with another oral P2Y

12platelet inhibitor.

How to take Ticagrelor — instructions & advice from the label

Advise the patient to read the FDA-approved patient labeling (Medication Guide)

Advise patients daily doses of aspirin should not exceed 100 mg and to avoid taking any other medications that contain aspirin.

Advise patients that they:

Will bleed and bruise more easily

Will take longer than usual to stop bleeding

Should report any unanticipated, prolonged or excessive bleeding, or blood in their stool or urine.

Advise patients to contact their doctor if they experience unexpected shortness of breath, especially if severe.

Advise patients to inform physicians and dentists that they are taking ticagrelor tablets before any surgery or dental procedure.

Advise women that breastfeeding is not recommended during treatment with ticagrelor

.

Distributed by:

Hisun Pharmaceuticals USA, Inc.

Bridgewater, NJ 08807

Manufactured in China.

Revised: 10/2026

TICAGRELOR (tye-KA-grel-or) Tablets

What is the most important information I should know about ticagrelor tablets?

Ticagrelor tablets are used to lower your chance of having, or dying from, a heart attack or stroke. …

Warnings & precautions

Do not take this medicine if: Ticagrelor is contraindicated in patients with a history of intracranial hemorrhage (ICH) because of a high risk of recurrent ICH in this population

.

Ticagrelor is contraindicated in patients with active pathological bleeding such as peptic ulcer or intracranial hemorrhage

.

Ticagrelor is contraindicated in patients with hypersensitivity (e.g., angioedema) to ticagrelor or any component of the product.

Drugs that inhibit platelet function including ticagrelor increase the risk of bleeding

.

Patients treated for acute ischemic stroke or TIA

Patients at NIHSS >5 and patients receiving thrombolysis were excluded from THALES and use of ticagrelor in such patients is not recommended.

Discontinuation of ticagrelor will increase the risk of myocardial infarction, stroke, and death in patients being treated for coronary artery disease. If ticagrelor must be temporarily discontinued (e.g., to treat bleeding or for significant surgery), restart it as soon as possible. When possible, interrupt therapy with ticagrelor for five days prior to surgery that has a major risk of bleeding. Resume ticagrelor as soon as hemostasis is achieved.

In clinical trials, about 21% (THEMIS) of patients treated with ticagrelor developed dyspnea. Dyspnea was usually mild to moderate in intensity and often resolved during continued treatment but led to study drug discontinuation in 1.0% (THALES) and 6.9% (THEMIS) of patients.

If a patient develops new, prolonged, or worsened dyspnea that is determined to be related to ticagrelor, no specific treatment is required; continue ticagrelor without interruption if possible. In the case of intolerable dyspnea requiring discontinuation of ticagrelor, consider prescribing another antiplatelet agent.

Ticagrelor can cause ventricular pauses

. Bradyarrhythmias including AV block have been reported in the postmarketing setting. …

Ticagrelor side effects

The following adverse reactions are also discussed elsewhere in the labeling:

Bleeding

Dyspnea

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

Ticagrelor has been evaluated for safety in more than 58,000 patients.

Bleeding in THEMIS (Prevention of major CV events in patients with CAD and Type 2 Diabetes Mellitus)

The Kaplan-Meier curve of time to first TIMI Major bleeding event is presented in Figure 3.

Figure 3 - Time to first TIMI Major bleeding event (THEMIS)

T = Ticagrelor; P = Placebo; N = Number of patients

The bleeding events in THEMIS are shown below in Table 6.

Table 6 – Bleeding events (THEMIS)

Ticagrelor

N=9562 | Placebo

N=9531

Events / 1000 patient years | Events / 1000 patient years

TIMI Major | 9 | 4

TIMI Major or Minor | 12 | 5

TIMI Major or Minor or Requiring medical attention | 46 | 18

Fatal bleeding | 1 | 0

Intracranial hemorrhage | 3 | 2

Bleeding in THALES (Reduction in risk of stroke in patients with acute ischemic stroke or TIA)

The Kaplan-Meier curve of time course of GUSTO severe bleeding events is presented in Figure 4. …

Drug interactions

Strong CYP3A inhibitors substantially increase ticagrelor exposure and so increase the risk of dyspnea, bleeding, and other adverse events. Avoid use of strong inhibitors of CYP3A (e.g., ketoconazole, itraconazole, voriconazole, clarithromycin, nefazodone, ritonavir, saquinavir, nelfinavir, indinavir, atazanavir and telithromycin)

.

Strong CYP3A inducers substantially reduce ticagrelor exposure and so decrease the efficacy of ticagrelor. Avoid use with strong inducers of CYP3A (e.g., rifampin, phenytoin, carbamazepine and phenobarbital)

.

As with other oral P2Y

12inhibitors, co-administration of opioid agonists delay and reduce the absorption of ticagrelor and its active metabolite presumably because of slowed gastric emptying

.

. Consider the use of a parenteral anti-platelet agent in acute coronary syndrome patients requiring co-administration of morphine or other opioid agonists.

Ticagrelor increases serum concentrations of simvastatin and lovastatin because these drugs are metabolized by CYP3A4. Avoid simvastatin and lovastatin doses greater than 40 mg

.

Ticagrelor increases serum concentration of rosuvastatin because rosuvastatin is a BCRP substrate. Avoid rosuvastatin doses greater than 20 mg

. …

About this medicine

Ticagrelor tablets contain ticagrelor, a cyclopentyltriazolopyrimidine, inhibitor of platelet activation and aggregation mediated by the P2Y

12ADP-receptor. Chemically it is (1

S,2

S,3

R,5

S)-3-[7-{[(1

R,2

S)-2-(3,4-difluorophenyl)cyclopropyl]amino}-5-(propylthio)-3

H-[1,2,3]-triazolo[4,5-

d]pyrimidin-3-yl]-5-(2-hydroxyethoxy)cyclopentane-1,2-diol. The empirical formula of ticagrelor is C

23H

28F

2N

6O

4S and its molecular weight is 522.57. The chemical structure of ticagrelor is:

Ticagrelor is a crystalline powder with an aqueous solubility of approximately 10 μg/mL at room temperature.

Ticagrelor 90 mg tablets for oral administration contain 90 mg of ticagrelor and the following ingredients: microcrystalline cellulose, pregelatinized starch, croscarmellose sodium, hypromellose E5, polyethylene glycol 4000, colloidal silicon dioxide, magnesium stearate, hypromellose 2910, titanium dioxide, polyethylene glycol 400, ferric oxide yellow, ferric oxide red, and ferrosoferric oxide. …

Disclaimer: This page is for general information only and is not medical advice. It is a condensed summary of the official FDA-approved label — it does not replace the full prescribing information or the advice of your doctor or pharmacist. Always follow your prescriber's instructions and read the medication guide that comes with your medicine.

Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID c4c1ca82-99bd-451a-ad77-7fe28c4ae3e8. Read the full official label on DailyMed.

Related medicines

Atorvastatin Metformin Losartan Semaglutide Insulin Glargine Empagliflozin Glipizide Insulin Lispro